Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BCX4430 (Galidesivir) in Healthy Subjects
NCT02319772Phase 1Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Dec 2014
- Primary completion
- Mar 2016
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Ebola virus disease (EVD), Marburg virus disease (MVD) and Filovirus infection comparing BCX4430 with Placebo (2 arms). Primary endpoint: Safety and Tolerability at 14 days. Started Dec 2014; status: completed.
02
Drugs
galidesivir
03
Conditions
Ebola virus disease (EVD)Marburg virus disease (MVD)Filovirus infection
Beyond the preview
Go deeper on NCT02319772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319772.